Bridging the gaps in 18F PET tracer development

被引：0
作者：
Michael G. Campbell
Joel Mercier
Christophe Genicot
Véronique Gouverneur
Jacob M. Hooker
Tobias Ritter
机构：
[1] Harvard University,Department of Chemistry and Chemical Biology
[2] Global Chemistry,Division of Nuclear Medicine and Molecular Imaging, Department of Radiology
[3] UCB NewMedicines,undefined
[4] UCB Biopharma SPRL,undefined
[5] Chemistry Research Laboratory,undefined
[6] University of Oxford,undefined
[7] Massachusetts General Hospital,undefined
[8] Athinoula A. Martinos Center for Biomedical Imaging,undefined
[9] Massachusetts General Hospital and Harvard Medical School,undefined
[10] Max-Planck-Institut für Kohlenforschung,undefined
[11] Present Address: Department of Chemistry,undefined
[12] Barnard College,undefined
[13] 3009 Broadway,undefined
[14] New York,undefined
[15] New York 10027,undefined
[16] USA,undefined
来源：
Nature Chemistry | 2017年 / 9卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
As compared to the drug discovery process, the development of new 18F PET tracers lacks a well-established pipeline that advances compounds from academic research to candidacy for (pre)clinical imaging. In order to bridge the gaps between methodological advances and clinical success, we must rethink the development process from training to implementation.
引用
收藏
页码：1 / 3
页数：2
相关论文
共 33 条
[1]  
Brown JM(2009)undefined Angew. Chem. Int. Ed. 48 8610-8614
[2]  
Gouverneur V(2011)undefined Nature 473 470-477
[3]  
Furuya T(2012)undefined Chem. Commun. 48 2929-2942
[4]  
Kamlet AS(2013)undefined Angew. Chem. Int. Ed. 52 8214-8264
[5]  
Ritter T(2015)undefined Chem. Rev. 115 612-633
[6]  
Hollingworth C(2008)undefined Chem. Rev. 108 1501-1516
[7]  
Gouverneur V(2012)undefined Angew. Chem. Int. Ed. 51 11426-11437
[8]  
Liang T(2014)undefined Chem. Sci. 5 4545-4553
[9]  
Neumann CN(2016)undefined Chem. Rev. 116 719-766
[10]  
Ritter T(2016)undefined ACS Cent. Sci. 2 128-130
1234